BTK Inhibitors in Mantle Cell Lymphoma

CE / CME

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.75 Medical Knowledge MOC points

Released: December 23, 2024

Expiration: June 22, 2025

Brad Kahl
Brad Kahl, MD
John P. Leonard
John P. Leonard, MD
Julie M. Vose
Julie M. Vose, MD, MBA

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in applying recent data and expert opinion for the use of BTK inhibitor–based therapy for patients with treatment-naive MCL?

2.

Patient Case: A 66-Yr-Old Man With Previously Treated MCL



  • A 66-yr-old man is diagnosed with TP53 wild-type MCL

    • He previously completed R-CHOP/R-DHAP plus HDT-ASCT → rituximab maintenance, but has evidence of relapse during rituximab maintenance



  • PET/CT scan shows diffuse burden adenopathy; bone marrow biopsy shows involvement with MCL (20% cellular; 20% MCL)

  • Medical history includes hypertension, coronary artery disease and type 2 diabetes

    • He is on 1 cardiac medication with a BP at home of 130/80



  • He started on zanubrutinib therapy, but presented to the ED with atypical angina with BP findings of 150/90 (grade 2)

  • His cardiac workup was negative for arrhythmia or ischemic etiology 

Which of the following would you recommend as a reasonable next step for this 66-yr-old patient?

3.

A patient with MCL is receiving acalabrutinib but reports difficulty adhering to the regimen because of persistent, mild headaches. What would you tell your patient?